A promising new form of medication aimed at treating Alzheimer's has showed signs that it may be four times more effective than the current pill.
This drug may be more effective than donepezil, the current pill, in preventing the onset and progression of the disease, Australian researchers said.
Preliminary results regarding the new wonder drug, known as Anavex 2-73 -- presented by researchers at the Alzheimer's Association International Conference (AAIC) in the US overnight -- showed that out of the 12 patients in the Alfred Health trial, 10 recorded improved cognitive function.
Residents of the Australian state of Victoria will have first access to the drug, Xinhua news agency reported.
The trial's head figure, associate professor Steve Macfarlane, director of aged care at Caulfield Hospital in Melbourne, said he was "cautiously optimistic" following the drug's early positive signs.
The amount of improvement in those tested in the 36-days study was greater than that expected of a donepezil-taker after six months.
"We've also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence," Macfarlane said.
It is estimated that more than 25 million people across the globe suffer Alzheimer's, which slowly deteriorates mental capabilities and is the leading cause of dementia.
The full results of the Australian trial are expected to be released at the end of the year.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
